The Regents Of The University Of California v. The Controller Of Patents

In the high-stakes world of biotech innovation, the line between a groundbreaking patent and a rejected application often comes down to one critical question: how broadly can you claim your invention? For one of the world's most prestigious research institutions, that question turned into a costly lesson when the Delhi High Court upheld the rejection of their patent application for a recombinant Salmonella-based live vaccine. This case serves as a stark reminder that even the most respected names in science cannot escape the fundamental requirements of patent law.

The Regents of the University of California, a globally recognized research powerhouse, filed a patent application for a recombinant Salmonella microorganism-based live vaccine. This was no ordinary filing—it represented potentially significant innovation in vaccine technology. However, the Controller of Patents raised serious concerns about the scope and substance of the application. The Controller identified two fundamental problems: first, the claims were drafted so broadly that they potentially encompassed naturally occurring loss-of-function variants of the microorganism; and second, the complete specification did not provide adequate disclosure or clarity to support the wide range of organisms being claimed. These objections led to the refusal of the patent application, prompting The Regents to appeal the decision before the Delhi High Court.

The Regents of the University of California argued that their invention deserved patent protection, presenting what they believed was a novel and useful contribution to vaccine technology. On the other side, the Controller of Patents mounted a two-pronged defense. The first argument centered on Section 3(c) of the Patents Act, which excludes certain products from patentability—specifically, the Controller contended that the broad claims swept in naturally occurring loss-of-function variants, effectively claiming products of nature that cannot be patented. The second argument attacked the foundation of the application itself: the Controller maintained that the specification failed to provide sufficient disclosure to enable a person skilled in the art to practice the invention across the wide range of organisms claimed. This created a fundamental legal friction between the university's desire for broad protection and the patent system's requirement for precise, enabled, and non-naturally-occurring subject matter.

The Delhi High Court sided with the Controller of Patents, dismissing the appeal and upholding the refusal of the patent application. The court's reasoning rested on two pillars: insufficient disclosure in the specification and non-patentability under Section 3(c) of the Patents Act. The court found that the complete specification did not provide the level of clarity and enablement required to support claims covering such a wide range of organisms. Additionally, the court agreed that the broad scope of the claims improperly encompassed naturally occurring variants, falling afoul of the prohibition against patenting products of nature. The outcome was a clear victory for the Controller and a significant setback for the university's patent ambitions.

For founders, startup leaders, and IP professionals, this case delivers a powerful lesson in patent strategy: breadth without support is a recipe for rejection. When drafting patent applications, especially in biotechnology, claims must be carefully calibrated to match what the specification actually enables and discloses. Overly broad claims that inadvertently cover naturally occurring variants will likely be struck down under Section 3(c) as unpatentable products of nature. Equally important, the specification must provide sufficient detail and clarity to support the full scope of what is being claimed. The takeaway is clear—pursue broad protection if you must, but only when your disclosure can back it up. Otherwise, even the most innovative inventions can be denied the patent shield they deserve.